ArticlePediatric rheumatology online journal2025
Neutrophil activation in juvenile dermatomyositis: associations with muscle function and disease progression.
Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundJuvenile dermatomyositis (JDM) is an inflammatory vasculopathy characterized by muscle weakness and systemic inflammation. This study aimed to investigate the clinical utility of neutrophil activation markers, specifically calprotectin (S100A8/A9) and myeloperoxidase (MPO)-DNA complexes, as potential biomarkers for muscle inflammation and predictors of muscle outcomes in JDM.
findingsPlasma levels of calprotectin and MPO-DNA were quantified using ELISA in JDM (n = 36), juvenile idiopathic arthritis (JIA, n = 13), and healthy controls (HCs, n = 21). Disease severity and muscle function were assessed using the Childhood Myositis Assessment Scale (CMAS), Physician Global Assessment (PGA), and Manual Muscle Testing 8 (MMT8). JDM patients exhibited significantly higher plasma calprotectin and MPO-DNA levels as compared to HCs (p = 0.0008 and p = 0.0048, respectively). Calprotectin levels correlated with muscle function scores (CMAS r=-0.682, p = 0.0002; MMT8 r=-0.59, p = 0.005; and PGA muscle scores r = 0.452, p = 0.014). Patients with elevated levels of both calprotectin and MPO-DNA tended to have greater disease activity and muscle involvement. Exploratory ROC analysis suggested that baseline calprotectin and MPO-DNA levels may help distinguish active disease. Notably, higher baseline levels of these markers correlated with improved MMT8 scores over time (r = 0.634, p = 0.027; r = 0.582, p = 0.047), suggesting an association with greater subsequent improvement in muscle strength.
conclusionsThese findings highlight calprotectin and MPO-DNA as potential biomarkers for JDM muscle inflammation and functional outcomes. These results suggest that neutrophil activation plays a key role in JDM pathogenesis and may provide insights into disease monitoring and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.